Drugs / UroVaxom
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02591901 | Apr 2018 → Aug 2019 | urinary tract infection | Buckinghamshire Healthcare NHS Trust | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04049994 | Jun 2020 → Sep 2023 | spinal cord injury, urinary tract infection | Swiss Paraplegic Research, Nottwil | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Uro-Vaxom | “Immunomodulation therapy with UroVaxom is a very promising method for the prevention of UTI, however data in individuals with SCI are very limited.” NCT04049994 ↗3“lyophilized lysate of E. coli strains for oral application (Uro-Vaxom®, OM Pharma SA, Meyrin, Switzerland).” PMID 34607600 ↗ Oct 2021 |
| Modality | Vaccine | “orally administered, bacterial vaccine” NCT02591901 ↗ |
| Route | Oral | “orally administered” NCT02591901 ↗ |